University of Pittsburgh-led study confirms that Raloxifene protects post-menopausal women from invasive bre...( Pittsburgh Feb. 13 -- The drug ralo...)

University of Pittsburgh-led study confirms that Raloxifene protects post-menopausal women from invasive breast cancer

Pittsburgh, Feb. 13 -- The drug raloxifene significantly reduces the risk of invasive breast cancer in post-menopausal women, according to results of a large-scale study involving the University of Pittsburgh Graduate School of Public Health (GSPH) and published in the upcoming issue of Breast Cancer Research and Treatment. The Multiple Outcomes of Raloxifene Evaluation (MORE) trial measured the effects of raloxifene, which has been approved by the U.S. Food and Drug Administration for the prevention and treatment of osteoporosis, on breast cancer rates after four years of follow-up. The results confirm the studys preliminary findings, which where published in the June 1999 issue of the Journal of the American Medical Association.

"The MORE trial showed that raloxifene reduces the risk of invasive breast cancer by 72 percent in women who took this drug daily for four years," said Jane Cauley, Dr.P.H., lead author on the study and associate professor of epidemiology at the GSPH. "Specifically, raloxifene reduced the risk of estrogen-receptor positive invasive breast cancer by 84 percent. This finding indicates that raloxifene is very effective at curbing the development of estrogen-fed breast tumors among older women with an average breast cancer risk."

MORE, a multi-center osteoporosis trial, involved 7,705 post-menopausal women, average age of 66.5 years, with a history of osteoporosis. About 12 percent reported a family history of breast cancer. Participants were randomly assigned to receive 60 mg or 120 mg of raloxifene per day or a placebo. Neither investigator nor participant knew who received placebos and who received raloxifene.

After four years, 22 cases of breast cancer were confirmed among the 5,129 women assigned to either dose of raloxifene, versus 39 cases among the 2,576 women assigned to the placebo. There were no significant differences in outcome between the group taking 60 mg of the drug and those taking 120 mg. Overall, ralo
'"/>

Contact: Kathryn Duda
dudak@msx.upmc.edu
412-624-2607
University of Pittsburgh Medical Center
12-Feb-2001

Page: 1 2 3
Related medicine news :

1. Indiana University researchers closer to helping hearing-impaired using stem cells
2. Boston University team finds link between high cholesterol and better cognitive performance
3. University seeks recruits for arthritis study
4. University of Manchester awarded 826k for brain science and mental health research
5. $4 million grant boosts University of Michigan campaign for a new childrens hospital
6. Lead in the environment causes violent crime, reports University of Pittsburgh researcher at AAAS
7. Next generation body scanner launched by the University of Manchester
8. University of Washington joins new Autism Treatment Network to provide better medical services
9. Binghamton University launches microelectronics research center
10. University of Manchester makes made-to-measure skin and bones a reality using inkjet printers
11. RelayHealth selected by Columbia University to link doctors and patients online

Post Your Comments: